Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

BACKGROUND AND AIMS: AGATE‐I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and 16 weeks' treatment with a combination of two direct‐acting antivirals, ombitasvir and paritaprevir (codosed with ritonavir), plus ribav...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Health Sci Rep
Main Authors: Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Yves, Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, Jose Luis, Bruno, Savino, Schnell, Gretja, Qaqish, Roula, Redman, Rebecca, Pilot‐Matias, Tami, Kopecky‐Bromberg, Sarah, Yu, Yao, Mobashery, Niloufar
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6427060/
https://ncbi.nlm.nih.gov/pubmed/30937389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hsr2.92
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados